LYS.PA - Lysogene S.A.
Lysogene S.A.
18-20 rue Jacques Dulud
Neuilly-sur-Seine 92200
France
33 1 41 43 03 90
https://www.lysogene.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 22
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Ms. Karen Pignet-Aiach MBA | Founder, Chairman & CEO | 455,13k | S.O. | 1971 |
| Mr. Come de La Tour du Pin | Chief Financial Officer | S.O. | S.O. | S.O. |
| Dr. Ralph Laufer | Chief Scientific Officer | S.O. | S.O. | S.O. |
| Dr. Marie Deneux | Chief Regulatory affairs | S.O. | S.O. | S.O. |
| Dr. Marie Trad | Chief Clinical Officer | S.O. | S.O. | S.O. |
Description
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a research collaboration with the Yeda Research and Development Co Ltd. for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was founded in 2009 and is based in Neuilly-sur-Seine, France.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Lysogene S.A. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..
